Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study

Highlight

– Upadacitinib therapy was associated with rapid MDA achievement by week 4 and substantial increases in MDA at weeks 24 and 48 in both oligoarticular and polyarticular PsA.

– After 24 weeks, 41.5% of patients overall achieved MDA (55.8% in oPsA; 32.0% in pPsA); benefits were largely maintained to week 48.